secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001140361-25-017704
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Q1 revenue up 40% to $114.8M; raises FY2025/2026 guidance; authorizes $500M buyback
--------------------------------------------------------------------------------

- Q1 total revenue $114.8M (+40% YoY); GAAP net income $26.9M (+51% YoY); adjusted EBITDA $47.9M (+81% YoY).
- FY2025 revenue guidance raised to >$500M; FY2026 to >$625M; adjusted EBITDA guidance >$235M and >$340M, respectively.
- Board authorized $500M share repurchase program (~8% of market cap); timing and amount discretionary.
- Debt reorganized: $30M borrowed on revolver to repay term loan; revolver outstanding $72.5M, term loan $2.5M; cost of debt down 1.1%.
- FDA-approved yield enhancement process expected to increase IG output 20% from same plasma volume, supporting future growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/0001140361-25-017704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/ef20048524_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-017704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer